share_log

424B3: Prospectus

424B3: Prospectus

424B3:募资说明书
美股SEC公告 ·  09/10 07:23

Moomoo AI 已提取核心信息

ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, has filed a prospectus related to the offer and resale of up to 478,600 shares of common stock by selling stockholders. These shares are issuable upon the exercise of Series A-1 and Series B-1 warrants acquired by the selling stockholders in a private placement that closed on August 2, 2024. ZyVersa will not sell any securities under this prospectus nor receive proceeds from the stock sales by the selling stockholders. However, if all warrants are exercised in cash at the exercise price of $3.46 per share, ZyVersa may receive approximately $1,655,956 in gross proceeds. The selling stockholders may sell the shares at varying prices and methods, including on the open market or through private transactions. The company...Show More
ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, has filed a prospectus related to the offer and resale of up to 478,600 shares of common stock by selling stockholders. These shares are issuable upon the exercise of Series A-1 and Series B-1 warrants acquired by the selling stockholders in a private placement that closed on August 2, 2024. ZyVersa will not sell any securities under this prospectus nor receive proceeds from the stock sales by the selling stockholders. However, if all warrants are exercised in cash at the exercise price of $3.46 per share, ZyVersa may receive approximately $1,655,956 in gross proceeds. The selling stockholders may sell the shares at varying prices and methods, including on the open market or through private transactions. The company has undergone reverse-stock-splits on December 4, 2023, and April 25, 2024, and the share information in the prospectus has been adjusted accordingly. ZyVersa's common stock is listed on The Nasdaq Stock Market under the symbol 'ZVSA'. The last reported sale price of ZyVersa's common stock was $2.77 per share as of August 30, 2024. The prospectus also outlines the risks associated with investing in ZyVersa's securities, including the company's ability to continue as a going concern and the need for additional capital to fund its operations and development programs.
致力于临床阶段生物制药公司的ZyVersa Therapeutics,Inc.已就售出的股票申报了招股书。这些股票由卖方股东持有,系在2024年8月2日结束的定向增发中获得的A-1系列和B-1系列权证行权产生的。ZyVersa不会在招股书下销售任何证券,也不会收到来自卖方股东股票销售的款项。但是,如果所有权证按每股3.46美元的行权价格以现金支付行权,ZyVersa可能会获得大约1,655,956美元的总收益。卖方股东可以以不同的价格和方式销售这些股票,包括在公开市场上或通过私人交易。公司于2023年12月4日和2024年4月25日进行了股票拆分,招股书中的股份信息已相应调整。ZyVersa的...展开全部
致力于临床阶段生物制药公司的ZyVersa Therapeutics,Inc.已就售出的股票申报了招股书。这些股票由卖方股东持有,系在2024年8月2日结束的定向增发中获得的A-1系列和B-1系列权证行权产生的。ZyVersa不会在招股书下销售任何证券,也不会收到来自卖方股东股票销售的款项。但是,如果所有权证按每股3.46美元的行权价格以现金支付行权,ZyVersa可能会获得大约1,655,956美元的总收益。卖方股东可以以不同的价格和方式销售这些股票,包括在公开市场上或通过私人交易。公司于2023年12月4日和2024年4月25日进行了股票拆分,招股书中的股份信息已相应调整。ZyVersa的普通股在纳斯达克股票市场上以“ZVSA”作为标的进行交易。截至2024年8月30日,ZyVersa的普通股的最后报价为每股2.77美元。招股书还概述了投资ZyVersa证券所涉及的风险,包括公司继续作为持续经营实体的能力以及为其业务和开发计划筹集额外资金的需求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息